TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Brii Biosciences Limited ( (HK:2137) ) just unveiled an update.
Brii Biosciences Limited has entered into a licensing agreement with Joincare Pharmaceutical Group to develop and commercialize BRII-693, a novel antibiotic for multidrug-resistant infections, in Greater China. This partnership leverages Joincare’s expertise in manufacturing and commercialization, aiming to address the critical unmet clinical needs for hospital antibiotics in the region, thereby enhancing Brii Biosciences’ strategic positioning in the anti-infection market.
The most recent analyst rating on (HK:2137) stock is a Hold with a HK$1.00 price target. To see the full list of analyst forecasts on Brii Biosciences Limited stock, see the HK:2137 Stock Forecast page.
More about Brii Biosciences Limited
Brii Biosciences Limited is a biopharmaceutical company focused on developing innovative therapies for infectious diseases. Their primary products include novel antibiotics targeting multidrug-resistant bacterial infections, with a market focus on Greater China.
Average Trading Volume: 3,933,697
Technical Sentiment Signal: Hold
Current Market Cap: HK$1.24B
See more insights into 2137 stock on TipRanks’ Stock Analysis page.